Company Description
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States.
The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.
It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox.
It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; and the Burnet Institute.
GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
| Country | United States |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | David Dodd |
Contact Details
Address: 1900 Lake Park Drive, Suite 380 Smyrna, Georgia 30080 United States | |
| Phone | (678) 384-7220 |
| Website | geovax.com |
Stock Details
| Ticker Symbol | GOVX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000832489 |
| CUSIP Number | 373678507 |
| ISIN Number | US3736786068 |
| Employer ID | 87-0455038 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David Alan Dodd | Chairman, President and Chief Executive Officer |
| Dr. Mark J. Newman Ph.D. | Chief Scientific Officer |
| Dr. Kelly T. McKee Jr., M.D., M.P.H. | Chief Medical Officer |
| Dr. Harriet Latham Robinson Ph.D. | Founder, Chief Scientific Officer Emeritus and Member of Scientific Advisory Board |
| Mark W. Reynolds CPA | Chief Financial Officer and Corporate Secretary |
| Thomas O'Brien | Vice President of Quality Systems and Compliance |
| Jeffrey Welch | Head of Process Development and Manufacturing Operations |
| Dr. John W. Sharkey Ph.D. | Vice President of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 1, 2025 | 424B3 | Prospectus |
| May 1, 2025 | 424B3 | Prospectus |
| May 1, 2025 | 424B3 | Prospectus |
| May 1, 2025 | 424B3 | Prospectus |
| May 1, 2025 | 424B3 | Prospectus |
| May 1, 2025 | 8-K | Current Report |
| May 1, 2025 | 10-Q | Quarterly Report |
| Apr 14, 2025 | 8-K | Current Report |
| Apr 14, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 28, 2025 | EFFECT | Notice of Effectiveness |